Smith & Wesson Brands, Inc. (SWBI)

CTI BioPharma Stock Forecast

Stock Price Forecast

The 2 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $12, which forecasts a 55.04% increase in the stock price over the next year. The lowest target is $11 and the highest is $13.

Price Target: $12.00 (+55.04%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$11	$12	$13	$13
Change	+42.12%	+55.04%	+67.96%	+67.96%

* Price targets were last updated on Jun 23, 2025.

Analyst Ratings

The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mark Smith Lake Street	Lake Street	Strong Buy Maintains $13 → $11	Strong Buy	Maintains	$13 → $11	+42.12%	Jun 23, 2025
Mark Smith Lake Street	Lake Street	Strong Buy Maintains $13 → $13	Strong Buy	Maintains	$13 → $13	+61.50%	Mar 7, 2025
Mark Smith Lake Street	Lake Street	Hold → Strong Buy Upgrades $13	Hold → Strong Buy	Upgrades	$13	+67.96%	Jan 27, 2025
Steve Dyer Craig-Hallum	Craig-Hallum	Strong Buy → Hold Downgrades $18 → $13	Strong Buy → Hold	Downgrades	$18 → $13	+67.96%	Dec 6, 2024
Mark Smith Lake Street	Lake Street	Strong Buy → Hold Downgrades $18 → $13	Strong Buy → Hold	Downgrades	$18 → $13	+67.96%	Dec 6, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

467.01M

Decreased by -1.61%

from 474.66M

Revenue Next Year

510.10M

Increased by 9.23%

from 467.01M

EPS This Year

0.16

Decreased by -45.60%

from 0.30

EPS Next Year

n/a

from 0.16

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Apr 30, 2021	Apr 30, 2022	Apr 30, 2023	Apr 30, 2024	Apr 30, 2025	Apr 30, 2026	Apr 30, 2027
Revenue	1.06B	864.13M	479.24M	535.83M	474.66M	467.01M	510.10M
Revenue Growth	99.99%	-18.42%	-44.54%	11.81%	-11.42%	-1.61%	9.23%
EPS	4.55	4.08	0.80	0.89	0.30	0.16	-
EPS Growth	-	-10.39%	-80.39%	11.25%	-66.29%	-45.60%	-
Forward PE	-	-	-	-	-	47.43	-
No. Analysts	-	-	-	-	-	5	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	496.1M	525.1M
Avg	467.0M	510.1M
Low	425.8M	490.1M

Revenue Growth

Revenue Growth	2026	2027
High	4.5%	12.4%
Avg	-1.6%	9.2%
Low	-10.3%	4.9%

EPS Forecast

EPS	2026
High	0.29
Avg	0.16
Low	0.04

EPS Growth

EPS Growth	2026
High	-2.0%
Avg	-45.6%
Low	-86.9%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.